Observational Study of MasSpec Pen for Neurofibroma and MPNST
This study is looking at a new handheld device called the MasSpec Pen. Researchers want to see if this device can accurately tell the difference between neurofibromas (non-cancerous nerve tumors), MPNSTs (Malignant Peripheral Nerve Sheath Tumors, a type of cancer), and normal tissue during surgery. The goal is to help doctors quickly diagnose these conditions and make sure all cancerous tissue is removed. You might be able to join if you are at least 1 year old and are having surgery for a neurofibroma or MPNST. The study will look at safety and any side effects over about one year. The study plans to include about 60 participants.
- Study design
- This is an observational study, meaning researchers will collect information without giving you a specific treatment. It plans to enroll about 60 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and any side effects will be monitored through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Keila Torres, MD,PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0